Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies

被引：9

作者：

Burger, Jan A. ^{[1
]}

Cramer, Paula ^{[2
]}

Barr, Paul M. ^{[3
]}

Dilhuydy, Marie-Sarah ^{[4
]}

Mato, Anthony ^{[5
]}

Byrd, John C. ^{[6
]}

Chang, Stephen ^{[7
]}

Graef, Thorsten ^{[7
]}

Lin, Tony ^{[7
]}

Tedeschi, Alessandra ^{[8
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Cologne, German CLL Study Grp, Cologne, Germany

[3] Univ Rochester, Canc Ctr, Rochester, NY USA

[4] Ctr Hosp Univ Bordeaux, Bordeaux, France

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Ohio State Univ, Columbus, OH 43210 USA

[7] Pharmacyclics LLC, Sunnyvale, CA USA

[8] Azienda Osped Niguarda Ca Granda, Milan, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 186卷 / 01期

关键词：

ibrutinib; Bruton's tyrosine kinase inhibitor; chronic lymphocytic leukaemia; survival outcomes; comorbidities; CHRONIC LYMPHOCYTIC-LEUKEMIA;

D O I：

10.1111/bjh.15784

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：175 / 180

页数：6

共 8 条

[1] Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model [J].

Baumann, Tycho ;

Delgado, Julio ;

Santacruz, Rodrigo ;

Martinez-Trillos, Alejandra ;

Royo, Cristina ;

Navarro, Alba ;

Pinyol, Magda ;

Rozman, Mara ;

Pereira, Arturo ;

Villamor, Neus ;

Aymerich, Marta ;

Lopez, Cristina ;

Carrio, Anna ;

Montserrat, Emili .

HAEMATOLOGICA, 2014, 99 (10) :1599-1604

[2] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[3]

Busch R., 2014, BLOOD, V124, P19, DOI [10.1182/blood.V124.21.19.19, DOI 10.1182/BLOOD.V124.21.19.19]

[4] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[5] Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study [J].

Chanan-Khan, Asher ;

Cramer, Paula ;

Demirkan, Fatih ;

Fraser, Graeme ;

Silva, Rodrigo Santucci ;

Grosicki, Sebastian ;

Pristupa, Aleksander ;

Janssens, Ann ;

Mayer, Jiri ;

Bartlett, Nancy L. ;

Dilhuydy, Marie-Sarah ;

Pylypenko, Halyna ;

Loscertales, Javier ;

Avigdor, Abraham ;

Rule, Simon ;

Villa, Diego ;

Samoilova, Olga ;

Panagiotidis, Panagiots ;

Goy, Andre ;

Mato, Anthony ;

Pavlovsky, Miguel A. ;

Karlsson, Claes ;

Mahler, Michelle ;

Salman, Mariya ;

Sun, Steven ;

Phelps, Charles ;

Balasubramanian, Sriram ;

Howes, Angela ;

Hallek, Michael ;

Assouline, S. ;

Bence-Bruckler, I. ;

Buckstein, R. ;

Fraser, G. ;

Larratt, L. ;

Minuk, L. ;

Villa, D. ;

Angevine, A. ;

Bartlett, N. ;

Bixby, D. ;

Caimi, P. ;

Chanan-Khan, A. ;

Craig, M. ;

Forero-Torres, A. ;

Ganguly, S. ;

Goy, A. ;

Heffner, L. ;

Hermann, R. ;

Lansigan, F. ;

Leis, J. ;

Letzer, J. .

LANCET ONCOLOGY, 2016, 17 (02) :200-211

[6] Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials [J].

Goede, Valentin ;

Cramer, Paula ;

Busch, Raymonde ;

Bergmann, Manuela ;

Stauch, Martina ;

Hopfinger, Georg ;

Stilgenbauer, Stephan ;

Doehner, Hartmut ;

Westermann, Anne ;

Wendtner, Clemens M. ;

Eichhorst, Barbara ;

Hallek, Michael .

HAEMATOLOGICA, 2014, 99 (06) :1095-1100

[7] Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib [J].

Gordon, Max J. ;

Churnetski, Michael ;

Alqahtani, Hamood ;

Rivera, Xavier ;

Kittai, Adam ;

Amrock, Stephen M. ;

James, Spencer ;

Hoff, Sheila ;

Manda, Sudhir ;

Spurgeon, Stephen E. ;

Choi, Michael ;

Cohen, Jonathon B. ;

Persky, Daniel ;

Danilov, Alexey V. .

CANCER, 2018, 124 (15) :3192-3200

[8] Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development [J].

Smelick, Gillian S. ;

Heffron, Timothy P. ;

Chu, Laura ;

Dean, Brian ;

West, David A. ;

DuVall, Scott L. ;

Lum, Bert L. ;

Budha, Nageshwar ;

Holden, Scott N. ;

Benet, Leslie Z. ;

Frymoyer, Adam ;

Dresser, Mark J. ;

Waret, Joseph A. .

MOLECULAR PHARMACEUTICS, 2013, 10 (11) :4055-4062

← 1 →